INNV customers relationship map

InnovAge (INNV): PACE-centered revenue with strategic health-system partners in Florida

InnovAge operates a focused healthcare delivery business that monetizes primarily through capitated, per-member-per-month (PMPM) payments under the Program of All‑Inclusive Care for the Elderly (PACE). The company serves dual‑eligible and high‑cost seniors directly, running 20 PACE centers and collecting recurring fees from Medicare, Medicaid, the VA and private payers; PACE services account for virtually all revenue, creating a highly predictable but concentrated cash flow profile. For a quick look at related commercial signals and customer relationships, see NullExposure’s research hub: https://nullexposure.com/.

How InnovAge’s model converts patient care into enterprise value

InnovAge is not a traditional fee-for-service health system. It functions as a capitated service provider, accepting fixed payments to deliver a comprehensive bundle of medical and ancillary services (primary care, in‑home care, therapies, mental health, transportation, meals, dental and care management). This contract posture converts clinical delivery into subscription-like recurring revenue with clear per‑participant economics—management cites an average annual revenue opportunity of about $115,000 per participant (≈ $9,600 PMPM). That structure drives revenue visibility and operational leverage when utilization and care management work in sync.

Yet that predictability comes with concentrated counterparty and program risk: InnovAge earns 99.8% of revenue from PACE, receives the majority of receivables from Medicaid (76%) and Medicare (21%), and operates exclusively in the United States across six states. These characteristics create a business that is stable in cash flow under steady policy regimes, but sensitive to regulatory, reimbursement, and enrollment shifts.

For more on how InnovAge’s customer and partner footprint influences valuation due diligence, visit NullExposure: https://nullexposure.com/.

Strategic and operational constraints that shape risk and upside

The company disclosures and associated reporting highlight several structural constraints that investors must translate into downside and upside scenarios:

Contracting posture — long‑term and subscription-like: InnovAge directly contracts with government payors on a PMPM capitation basis. This creates recurring revenue and visibility, but it also fixes revenue exposure to negotiated PMPM rates and regulatory changes. The capitation model rewards efficient care coordination and penalizes cost overruns.
Counterparty concentration — government‑facing revenue: The revenue base is highly tied to government programs (Medicaid/Medicare and the VA). That reduces commercial volatility but increases policy and reimbursement risk, particularly in states where Medicaid funding and enrollment rules can change.
Customer concentration — individual participants as the economic unit: Participants enroll in PACE and are the direct customers; InnovAge’s economics scale per participant. Operational performance (enrollment growth, retention, per‑participant cost control) directly maps to revenue growth and margin expansion.
Geography and maturity — U.S. only, concentrated center footprint: All assets and revenue are U.S. domiciled; InnovAge operates 20 centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia and served ~7,740 participants as of June 30, 2025. This footprint supports market leadership in PACE but limits immediate geographic diversification.
Materiality and criticality — single program dependence: PACE accounted for 99.8% of revenue in the two most recent fiscal years. That makes the program critical to enterprise value and any adverse programmatic developments would have outsized financial impact.
Average spend and unit economics — meaningfully material per enrollee: Company disclosures estimate roughly $115k in annual revenue per participant, a substantial per‑unit dollar value that magnifies both operational execution and reimbursement risk.

Collectively, these constraints position InnovAge as a highly specialized healthcare operator: recurring and visible cash flows underpinned by capitated contracts, but with concentrated policy and counterparty exposure that must be modeled explicitly in valuation scenarios.

Customer relationships: what investors need to know

Below I cover the disclosed customer/partner relationships from recent reporting and related press, with concise takeaways and source references.

Orlando Health — joint venture to expand PACE in Florida

InnovAge has pursued a strategic partnership with Orlando Health to expand PACE centers in Florida, using joint‑venture structures to accelerate local growth and leverage health‑system capabilities. This partnership is presented in InnovAge’s public reporting and summarized in TradingView coverage of the company’s SEC filings in May 2026. (TradingView reporting on InnovAge SEC 10‑Q, May 3, 2026 — https://www.tradingview.com/news/tradingview:7b2181f4d858d:0-innovage-holding-corp-sec-10-q-report/)

Tampa General Hospital — JV for a PACE center in Tampa

InnovAge entered into a joint venture with Tampa General Hospital specifically to develop a PACE center in the Tampa market, reflecting a strategy of co‑locating with or partnering alongside established health systems to gain referral flows and clinical integration. This is documented in the same TradingView summary of InnovAge’s SEC disclosures in May 2026. (TradingView reporting on InnovAge SEC 10‑Q, May 3, 2026 — https://www.tradingview.com/news/tradingview:7b2181f4d858d:0-innovage-holding-corp-sec-10-q-report/)

Why these relationships matter for investors

The Orlando Health and Tampa General Hospital joint ventures illustrate InnovAge’s go‑to‑market playbook: extending PACE capacity by partnering with established regional health systems rather than building entirely standalone centers. That approach accelerates market entry, can improve referral quality, and shares execution risk with institutional partners. From a valuation perspective:

Upside: Successful health‑system partnerships can drive faster enrollment, lower customer acquisition costs, and improved clinical integration—each lifting margin potential under capitation economics.
Downside: Joint ventures require coordination, shared governance, and can dilute control over local operations; poor partner alignment could slow enrollment or increase operational friction.

Investment implications and headline risks

For investors and operators evaluating INNV as a customer or investment:

Core thesis: InnovAge delivers subscription‑like, capitated revenue streams at high per‑participant dollar values, giving visibility to top‑line growth when enrollment expands and per‑participant cost is managed.
Key sensitivities: policy/regulatory changes to Medicaid/Medicare reimbursement, enrollment dynamics in aging populations, and execution on new center rollouts or joint venture integrations.
Balance sheet and market context: Market cap and margins indicate a growth narrative priced with some premium; institutional float is limited and insiders hold a large share, which affects liquidity and potential governance dynamics.

Bottom line

InnovAge’s model is straightforward: run PACE well, grow participants and centers (often via health‑system joint ventures), and convert per‑participant capitation into recurring enterprise value. The Orlando Health and Tampa General Hospital partnerships are tactical extensions of that strategy in Florida and illustrate the company’s preference for collaborative expansion with established providers.

For a centralized view of InnovAge customer signals and comparable relationship intelligence, explore NullExposure’s research portal: https://nullexposure.com/.

INNV customer relationships